These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

296 related items for PubMed ID: 27569835

  • 21. Effect of pimobendan on physical fitness, lactate and echocardiographic parameters in dogs with preclinical mitral valve disease without cardiomegaly.
    Iwanuk N, Wall L, Nolte I, Raue J, Rumstedt K, Pilgram A, Sehn M, Rohn K, Bach JP.
    PLoS One; 2019; 14(10):e0223164. PubMed ID: 31581204
    [Abstract] [Full Text] [Related]

  • 22. Left ventricular twist and circumferential strain in dogs with myxomatous mitral valve disease.
    Zois NE, Olsen NT, Moesgaard SG, Rasmussen CE, Falk T, Häggström J, Pedersen HD, Møller JE, Olsen LH.
    J Vet Intern Med; 2013; 27(4):875-83. PubMed ID: 23731222
    [Abstract] [Full Text] [Related]

  • 23. Efficacy of pimobendan on survival and reoccurrence of pulmonary edema in canine congestive heart failure.
    Mizuno M, Yamano S, Chimura S, Hirakawa A, Takusagawa Y, Sawada T, Maetani S, Takahashi A, Mizuno T, Harada K, Shinoda A, Uchida S, Takeuchi J, Mizukoshi T, Endo M, Uechi M.
    J Vet Med Sci; 2017 Jan 20; 79(1):29-34. PubMed ID: 27644192
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. R-R interval variations influence the degree of mitral regurgitation in dogs with myxomatous mitral valve disease.
    Reimann MJ, Møller JE, Häggström J, Markussen B, Holen AE, Falk T, Olsen LH.
    Vet J; 2014 Mar 20; 199(3):348-54. PubMed ID: 24507881
    [Abstract] [Full Text] [Related]

  • 27. Apoptosis and abundance of Bcl-2 family and transforming growth factor β1 signaling proteins in canine myxomatous mitral valves.
    Surachetpong S, Jiranantasak T, Rungsipipat A, Orton EC.
    J Vet Cardiol; 2013 Sep 20; 15(3):171-80. PubMed ID: 23816827
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. The longitudinal outcome of canine (K9) myxomatous mitral valve disease (LOOK-Mitral) registry: Baseline treatment characteristics.
    Franchini A, Borgarelli M, Abbott JA, Menciotti G, Crosara S, Häggström J, Lahmers S, Rosenthal S, Tyrrell W.
    J Vet Cardiol; 2022 Jun 20; 41():99-120. PubMed ID: 35316716
    [Abstract] [Full Text] [Related]

  • 32. Associations between N-terminal procollagen type III, fibrosis and echocardiographic indices in dogs that died due to myxomatous mitral valve disease.
    Hezzell MJ, Falk T, Olsen LH, Boswood A, Elliott J.
    J Vet Cardiol; 2014 Dec 20; 16(4):257-64. PubMed ID: 25292459
    [Abstract] [Full Text] [Related]

  • 33. Prevalence and prognostic importance of pulmonary hypertension in dogs with myxomatous mitral valve disease.
    Borgarelli M, Abbott J, Braz-Ruivo L, Chiavegato D, Crosara S, Lamb K, Ljungvall I, Poggi M, Santilli RA, Haggstrom J.
    J Vet Intern Med; 2015 Dec 20; 29(2):569-74. PubMed ID: 25818210
    [Abstract] [Full Text] [Related]

  • 34. Two-dimensional echocardiographic estimates of left atrial function in healthy dogs and dogs with myxomatous mitral valve disease.
    Dickson D, Caivano D, Matos JN, Summerfield N, Rishniw M.
    J Vet Cardiol; 2017 Dec 20; 19(6):469-479. PubMed ID: 29111284
    [Abstract] [Full Text] [Related]

  • 35. Evaluation of pimobendan and N-terminal probrain natriuretic peptide in the treatment of pulmonary hypertension secondary to degenerative mitral valve disease in dogs.
    Atkinson KJ, Fine DM, Thombs LA, Gorelick JJ, Durham HE.
    J Vet Intern Med; 2009 Dec 20; 23(6):1190-6. PubMed ID: 19780931
    [Abstract] [Full Text] [Related]

  • 36. The prevalence of pulmonary hypertension in Cavalier King Charles spaniels compared with other breeds with myxomatous mitral valve disease.
    Sudunagunta S, Green D, Christley R, Dukes-McEwan J.
    J Vet Cardiol; 2019 Jun 20; 23():21-31. PubMed ID: 31174726
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Sildenafil improves heart rate variability in dogs with asymptomatic myxomatous mitral valve degeneration.
    Pirintr P, Saengklub N, Limprasutr V, Sawangkoon S, Kijtawornrat A.
    J Vet Med Sci; 2017 Sep 12; 79(9):1480-1488. PubMed ID: 28717064
    [Abstract] [Full Text] [Related]

  • 39. Holter monitoring of small breed dogs with advanced myxomatous mitral valve disease with and without a history of syncope.
    Rasmussen CE, Falk T, Domanjko Petrič A, Schaldemose M, Zois NE, Moesgaard SG, Ablad B, Nilsen HY, Ljungvall I, Höglund K, Häggström J, Pedersen HD, Bland JM, Olsen LH.
    J Vet Intern Med; 2014 Sep 12; 28(2):363-70. PubMed ID: 24417236
    [Abstract] [Full Text] [Related]

  • 40. Effect of pimobendan on echocardiographic values in dogs with asymptomatic mitral valve disease.
    Ouellet M, Bélanger MC, Difruscia R, Beauchamp G.
    J Vet Intern Med; 2009 Sep 12; 23(2):258-63. PubMed ID: 19143935
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.